$4.56
2.77% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US8883143096
Symbol
TTNP
Sector
Industry

Titan Pharmaceuticals, Inc. Stock price

$4.56
-0.67 12.81% 1M
+1.09 31.41% 6M
+1.30 39.88% YTD
-2.38 34.29% 1Y
-186.24 97.61% 5Y
-574,393.44 100.00% 10Y
+2.44 115.09% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.13 2.77%
ISIN
US8883143096
Symbol
TTNP
Sector
Industry

Key metrics

Market capitalization $4.17m
Enterprise Value $2.22m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.22
Free Cash Flow (TTM) Free Cash Flow $-4.13m
Cash position $1.95m
Short interest 0.20%

Is Titan Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Financial data from Titan Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.56 4.56
18% 18%
-
- Research and Development Expense - -
-
-
-4.55 -4.55
37% 37%
-
- Depreciation and Amortization 0.01 0.01
91% 91%
-
EBIT (Operating Income) EBIT -4.56 -4.56
37% 37%
-
Net Profit -4.71 -4.71
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Titan Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Titan Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan'...
Neutral
GlobeNewsWire
2 months ago
NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company's newly designated Series B Convertible Preferred Stock (the “Preferred Sto...

Company Profile

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Chay
Employees 4
Founded 1992
Website www.titanpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today